UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.884-890

2018

Volltextzugriff (PDF)

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials

European journal of cancer (1990), 2021-05, Vol.148, p.76-91

2021

Volltextzugriff (PDF)

Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art

Current opinion in oncology, 2017-07, Vol.29 (4), p.243-252

2017

Volltextzugriff (PDF)

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

NPJ breast cancer, 2019-01, Vol.5 (1), p.5-5, Article 5

2019

Volltextzugriff (PDF)

Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials

Current opinion in oncology, 2024-09, Vol.36 (5), p.418-420

2024

Volltextzugriff (PDF)

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

The lancet oncology, 2012-09, Vol.13 (9), p.897-905

2012

Volltextzugriff (PDF)

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1301-1307

2010

Volltextzugriff (PDF)

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2586-2592

2013

Volltextzugriff (PDF)

Learning from the “Tsunami” of immune checkpoint inhibitors in 2015

Critical reviews in oncology/hematology, 2016-05, Vol.101, p.213-220

2016

Volltextzugriff (PDF)

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

The New England journal of medicine, 2007-10, Vol.357 (17), p.1695-1704

2007

Volltextzugriff (PDF)

The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives

Immunotherapy, 2017-06, Vol.9 (8), p.647-657

2017

Volltextzugriff (PDF)

RTK Inhibitors in Melanoma: From Bench to Bedside

Cancers, 2021-04, Vol.13 (7), p.1685

2021

Volltextzugriff (PDF)

Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

The oncologist (Dayton, Ohio), 2007-12, Vol.12 (12), p.1443-1455

2007

Volltextzugriff (PDF)

Potential involvement of the IL-33–ST2 axis in the pathogenesis of primary Sjögren's syndrome

Annals of the rheumatic diseases, 2014-06, Vol.73 (6), p.1259-1263

2014

Volltextzugriff (PDF)

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives

Therapeutic Advances in Medical Oncology, 2018-01, Vol.10, p.1758835918780312-1758835918780312

2018

Volltextzugriff (PDF)

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer

Frontiers in immunology, 2017-10, Vol.8, p.1412-1412

2017

Volltextzugriff (PDF)

Novel mechanisms and approaches in the medical therapy of solid cancers

Discovery medicine, 2015-07, Vol.20 (108), p.33-41

2015

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Journal of clinical oncology, 2005-02, Vol.23 (5), p.965-972

2005

Volltextzugriff (PDF)

Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer

Critical reviews in oncology/hematology, 2012-11, Vol.84 (2), p.149-160

2012

Volltextzugriff (PDF)

Rare side-effects of checkpoint inhibitors

Current opinion in oncology, 2016-07, Vol.28 (4), p.295-305

2016

Volltextzugriff (PDF)

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience

Breast (Edinburgh), 2021-06, Vol.57, p.86-94

2021

Volltextzugriff (PDF)

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Journal of clinical oncology, 2010-09, Vol.28 (25), p.3922-3928

2010

Volltextzugriff (PDF)

Abstract CN09-01: Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.CN09-01-CN09-01

Awada, Ahmad

2019

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Clinical cancer research, 2017-11, Vol.23 (21), p.6411-6420

2017

Volltextzugriff (PDF)

1 – 25 von 563

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(452)
Mit Volltextzugriff
(478)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(350)
Life Sciences & Biomedicine
(298)
Oncology
(242)
Humans
(233)
Female
(129)
Aged
(87)
Middle Aged
(85)
Adult
(75)
Breast Cancer
(74)
Tumors
(71)
Antineoplastic Agents - Therapeutic Use
(68)
Breast Neoplasms - Drug Therapy
(65)
Chemotherapy
(64)
Male
(63)
Neoplasms - Drug Therapy
(57)
Biological And Medical Sciences
(52)
Medical Sciences
(52)
Technology
(49)
Cancer Therapies
(47)
Patients
(44)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials

Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

Learning from the “Tsunami” of immune checkpoint inhibitors in 2015

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives

RTK Inhibitors in Melanoma: From Bench to Bedside

Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

Potential involvement of the IL-33–ST2 axis in the pathogenesis of primary Sjögren's syndrome

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer

Novel mechanisms and approaches in the medical therapy of solid cancers

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer

Rare side-effects of checkpoint inhibitors

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Abstract CN09-01: Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Suchergebnisse filtern